<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LEVOPHED- norepinephrine bitartrateÂ injection, solution, concentrateÂ </strong><br>Hospira, Inc.<br></p></div>
<h1>Levophedâ„¢ Norepinephrine Bitartrate Injection, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="d1907274-e116-4a65-9db9-fbb0a4a95f53"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First">Rx only</p>
<p><span class="Bold"><span class="Emphasis">NOVAPLUS<span class="Sup">Â®</span></span></span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="cc790363-bf1d-46ef-aeba-b740395dc728"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Norepinephrine (sometimes referred to as <span class="Italics"><span class="Emphasis">l-arterenol/Levarterenol</span></span> or<span class="Italics"><span class="Emphasis"> l-norepinephrine</span></span>) is a sympathomimetic amine which differs from epinephrine by the absence of a methyl group on the nitrogen atom.</p>
<p>Norepinephrine Bitartrate is (-)-Î±-(aminomethyl)-3,4-dihydroxybenzyl alcohol tartrate (1:1) (salt) monohydrate and has the following structural formula:</p>
<p><img alt="Norepinephrine-Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2b5320e-e6a6-4a43-8f3c-9c21195ceb4a&amp;name=levophed-injection-usp4-figure-1-en-3601_chem-str.jpg"></p>
<p>LEVOPHED is supplied in sterile aqueous solution in the form of the bitartrate salt to be administered by intravenous infusion following dilution. Norepinephrine is sparingly soluble in water, very slightly soluble in alcohol and ether, and readily soluble in acids. Each mL contains the equivalent of 1 mg base of norepinephrine, sodium chloride for isotonicity, and not more than 0.2 mg of sodium metabisulfite as an antioxidant. It has a pH of 3 to 4.5. The air in the vials has been displaced by nitrogen gas.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="f26614bf-6312-4026-888b-fee282426b7e"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">LEVOPHED functions as a peripheral vasoconstrictor (alpha-adrenergic action) and as an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action).</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="c9c80b34-e037-4f3e-b021-efffba79a3b5"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">For blood pressure control in certain acute hypotensive states (e.g., pheochromocytomectomy, sympathectomy, <span class="product-label-link" type="condition" conceptid="136330" conceptname="Acute nonparalytic poliomyelitis">poliomyelitis</span>, spinal anesthesia, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>, blood transfusion, and drug reactions).</p>
<p>As an adjunct in the treatment of <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> and profound <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="eb9a5cc5-492f-403e-9490-84bfd311d0a9"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">LEVOPHED should not be given to patients who are hypotensive from blood volume deficits except as an emergency measure to maintain coronary and cerebral artery perfusion until blood volume replacement therapy can be completed. If LEVOPHED is continuously administered to maintain blood pressure in the absence of blood volume replacement, the following may occur: severe peripheral and visceral <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, decreased renal perfusion and urine output, poor systemic blood flow despite â€œnormalâ€? blood pressure, tissue <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, and lactate <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>.</p>
<p>LEVOPHED should also not be given to patients with mesenteric or peripheral vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> (because of the risk of increasing <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> and extending the area of <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>) unless, in the opinion of the attending physician, the administration of LEVOPHED is necessary as a life-saving procedure.</p>
<p>Cyclopropane and halothane anesthetics increase cardiac autonomic <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> and therefore seem to sensitize the myocardium to the action of intravenously administered epinephrine or norepinephrine. Hence, the use of LEVOPHED during cyclopropane and halothane anesthesia is generally considered contraindicated because of the risk of producing <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> or <span class="product-label-link" type="condition" conceptid="4226399" conceptname="Fibrillation">fibrillation</span>.</p>
<p>The same type of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> may result from the use of LEVOPHED in patients with profound <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> or <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercarbia</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="c6a9aeed-4a5e-4f33-8e3d-821ecb1f3f52"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">LEVOPHED should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe, prolonged <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> may result.</p>
<p>LEVOPHED Bitartrate Injection contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown. Sulfite sensitivity is seen more frequently in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> than in nonasthmatic people.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ae7df2f5-74b5-4f32-a2f4-09d44deea321"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"><span class="Bold"><span class="Emphasis">General</span></span></p>
<p><span class="Bold"><span class="Emphasis">Avoid <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></span>: Because of the potency of LEVOPHED and because of varying response to pressor substances, the possibility always exists that dangerously high blood pressure may be produced with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of this pressor agent. It is desirable, therefore, to record the blood pressure every two minutes from the time administration is started until the desired blood pressure is obtained, then every five minutes if administration is to be continued.</p>
<p>The rate of flow must be watched constantly, and the patient should never be left unattended while receiving LEVOPHED. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> may be a symptom of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> due to overdosage.</p>
<p><span class="Bold"><span class="Emphasis">Site of Infusion</span></span>: Whenever possible, infusions of LEVOPHED should be given into a large vein, particularly an antecubital vein because, when administered into this vein, the risk of <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> of the overlying skin from prolonged <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> is apparently very slight. Some authors have indicated that the femoral vein is also an acceptable route of administration. A catheter tie-in technique should be avoided, if possible, since the obstruction to blood flow around the tubing may cause stasis and increased local concentration of the drug. Occlusive vascular diseases (for example, <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>, <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">arteriosclerosis</span>, diabetic <span class="product-label-link" type="condition" conceptid="314659" conceptname="Arteritis">endarteritis</span>, Buergerâ€™s disease) are more likely to occur in the lower than in the upper extremity. Therefore, one should avoid the veins of the leg in elderly patients or in those suffering from such disorders. <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">Gangrene</span> has been reported in a lower extremity when infusions of LEVOPHED were given in an ankle vein.</p>
<p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span></span></span>: <span class="Underline"><span class="Emphasis">The infusion site should be checked frequently for free flow</span></span>. Care should be taken to avoid <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> of LEVOPHED into the tissues, as local <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> might ensue due to the vasoconstrictive action of the drug. <span class="Underline"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">Blanching</span> along the course of the infused vein</span></span>, sometimes without obvious <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>, has been attributed to vasa vasorum constriction with increased permeability of the vein wall, permitting some leakage.</p>
<p>This also may progress on rare occasions to superficial slough, particularly during infusion into leg veins in elderly patients or in those suffering from obliterative vascular disease. Hence, if <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">blanching</span> occurs, consideration should be given to the advisability of changing the infusion site at intervals to allow the effects of local <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> to subside.</p>
<table width=" 1280px"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule">Â IMPORTANT â€” <span class="Bold"><span class="Emphasis">Antidote for <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">Ischemia</span>: </span></span>To prevent <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">sloughing</span> and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> in areas in which <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> has taken place, the area should be infiltrated as soon as possible with 10 mL to 15Â mL of saline solution containing from 5 mg to 10 mg of <span class="Bold"><span class="Emphasis">Regitine<span class="Sup">Â®</span> (brand of phentolamine)</span></span>, an adrenergic blocking agent. A syringe with a fine hypodermic needle should be used, with the solution being infiltrated liberally throughout the area, which is easily identified by its <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, hard, and pallid appearance. Sympathetic blockade with phentolamine causes immediate and conspicuous local hyperemic changes if the area is infiltrated within 12 hours. Therefore, <span class="Underline"><span class="Emphasis">phentolamine should be given as soon as possible</span></span> after the <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> is noted.</td></tr></tbody></table>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="d04d9cb9-ede1-4b43-8c21-fb8472077059"></a><a name="section-8"></a><p></p>
<h1>Drug Interactions</h1>
<p class="First">Cyclopropane and halothane anesthetics increase cardiac autonomic <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> and therefore seem to sensitize the myocardium to the action of intravenously administered epinephrine or norepinephrine. Hence, the use of LEVOPHED during cyclopropane and halothane anesthesia is generally considered contraindicated because of the risk of producing <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> or <span class="product-label-link" type="condition" conceptid="4226399" conceptname="Fibrillation">fibrillation</span>. The same type of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> may result from the use of LEVOPHED in patients with profound <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> or <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercarbia</span>.</p>
<p>LEVOPHED should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe, prolonged <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> may result.</p>
<br>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="e7116d36-7a5c-47e2-9719-43d53d0998a9"></a><a name="section-9"></a><p></p>
<h1>Carcinogenesis, Mutagenesis, Impairment of Fertility:</h1>
<p class="First">Studies have not been performed.</p>
<p><span class="Bold"><span class="Emphasis"><span class="Italics">Pregnancy Category C:</span></span></span> Animal reproduction studies have not been conducted with LEVOPHED. It is also not known whether LEVOPHED can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. LEVOPHED should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="e25ee0c0-dc4b-453b-acfd-cd99ccfc1449"></a><a name="section-10"></a><p></p>
<h1>Nursing Mothers</h1>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when LEVOPHED is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ef7dc4d0-e3d9-4b6c-820e-4778e841b585"></a><a name="section-11"></a><p></p>
<h1>Pediatric Use</h1>
<p class="First">Safety and effectiveness in pediatric patients has not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="e3881591-1600-465a-bb54-cde7c2899cdf"></a><a name="section-12"></a><p></p>
<h1>Geriatric Use</h1>
<p class="First">Clinical studies of LEVOPHED did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>LEVOPHED infusions should not be administered into the veins in the leg in elderly patients (see <a href="#ae7df2f5-74b5-4f32-a2f4-09d44deea321">PRECAUTIONS</a>, <a href="#ae7df2f5-74b5-4f32-a2f4-09d44deea321">General</a>).</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="a3c49171-b60e-4591-accb-47f1aee9b489"></a><a name="section-13"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The following reactions can occur:</p>
<p><span class="Italics"><span class="Emphasis">Body As A Whole</span></span>: Ischemic injury due to potent vasoconstrictor action and tissue <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>.<br><span class="Italics"><span class="Emphasis">Cardiovascular System</span></span>: <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, probably as a reflex result of a <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">rise in blood pressure</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>.<br><span class="Italics"><span class="Emphasis">Nervous System</span></span>: <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>, transient <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.<br><span class="Italics"><span class="Emphasis">Respiratory System</span></span>: Respiratory difficulty.<br><span class="Italics"><span class="Emphasis">Skin and Appendages</span></span>: <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> at injection site.</p>
<p>Prolonged administration of any potent vasopressor may result in plasma <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> which should be continuously corrected by appropriate fluid and electrolyte replacement therapy. If plasma volumes are not corrected, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> may recur when LEVOPHED is discontinued, or blood pressure may be maintained at the risk of severe peripheral and visceral <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> (e.g., decreased renal perfusion) with diminution in blood flow and tissue perfusion with subsequent tissue <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> and <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> and possible ischemic injury. <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">Gangrene</span> of extremities has been rarely reported.</p>
<p><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdoses</span> or conventional doses in hypersensitive persons (e.g., hyperthyroid patients) cause severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> with violent <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, stabbing <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">retrosternal pain</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, intense <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="f0dbdf73-ea70-4096-a94d-1a904b9c6421"></a><a name="section-14"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Overdosage with LEVOPHED may result in <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">reflex bradycardia</span>, marked increase in peripheral resistance, and decreased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>. In case of accidental overdosage, as evidenced by excessive blood pressure elevation, discontinue LEVOPHED until the condition of the patient stabilizes.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="b6043b92-c2dc-4bb9-bea1-de2e165d5338"></a><a name="section-15"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold"><span class="Emphasis">Norepinephrine Bitartrate Injection is a concentrated, potent drug which must be diluted in dextrose containing solutions prior to infusion. An infusion of LEVOPHED should be given into a large vein (see <a href="#ae7df2f5-74b5-4f32-a2f4-09d44deea321">PRECAUTIONS</a>).</span></span></p>
<p><span class="Bold"><span class="Emphasis">Restoration of Blood Pressure in Acute Hypotensive States</span></span><br>
    Blood <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> should always be corrected as fully as possible before any vasopressor is administered. When, as an emergency measure, intraaortic pressures must be maintained to prevent cerebral or coronary artery <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, LEVOPHED can be administered before and concurrently with blood volume replacement.</p>
<p><span class="Bold"><span class="Emphasis">Diluent: </span></span>LEVOPHED should be diluted in 5 percent dextrose injection or 5 percent dextrose and sodium chloride injections. These dextrose containing fluids are protection against significant loss of potency due to oxidation. <span class="Bold"><span class="Emphasis">Administration in saline solution alone is not recommended. </span></span>Whole blood or plasma, if indicated to increase blood volume, should be administered separately (for example, by use of a Y-tube and individual containers if given simultaneously).</p>
<p><span class="Italics"><span class="Emphasis">Average Dosage:</span></span> Add the content of the vial (4 mg/4 mL) of LEVOPHED to 1,000 mL of a 5 percent dextrose containing solution. Each mL of this dilution contains 4 mcg of the base of LEVOPHED. Give this solution by intravenous infusion. Insert a plastic intravenous catheter through a suitable bore needle well advanced centrally into the vein and securely fixed with adhesive tape, avoiding, if possible, a catheter tie-in technique as this promotes stasis. An IV drip chamber or other suitable metering device is essential to permit an accurate estimation of the rate of flow in drops per minute. After observing the response to an initial dose of 2 mL to 3 mL (from 8 mcg to 12 mcg of base) per minute, adjust the rate of flow to establish and maintain a low normal blood pressure (usually 80 mm Hg to 100 mm Hg systolic) sufficient to maintain the circulation to vital organs. In previously hypertensive patients, it is recommended that the blood pressure should be raised no higher than 40 mm Hg below the preexisting systolic pressure. The average maintenance dose ranges from 0.5 mL to 1 mL per minute (from 2 mcg to 4 mcg of base).</p>
<p><span class="Italics"><span class="Emphasis">High Dosage:</span></span> Great individual variation occurs in the dose required to attain and maintain an adequate blood pressure. In all cases, dosage of LEVOPHED should be titrated according to the response of the patient. Occasionally much larger or even enormous daily doses (as high as 68 mg base or 17 vials) may be necessary if the patient remains hypotensive, but occult blood <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> should always be suspected and corrected when present. Central venous pressure monitoring is usually helpful in detecting and treating this situation.</p>
<p><span class="Italics"><span class="Emphasis">Fluid Intake:</span></span> The degree of dilution depends on clinical fluid volume requirements. If large volumes of fluid (dextrose) are needed at a flow rate that would involve an excessive dose of the pressor agent per unit of time, a solution more dilute than 4 mcg per mL should be used. On the other hand, when large volumes of fluid are clinically undesirable, a concentration greater than 4 mcg per mL may be necessary.</p>
<p><span class="Italics"><span class="Emphasis">Duration of Therapy:</span></span> The infusion should be continued until adequate blood pressure and tissue perfusion are maintained without therapy. Infusions of LEVOPHED should be reduced gradually, avoiding abrupt withdrawal. In some of the reported cases of <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">vascular collapse</span> due to <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, treatment was required for up to six days.</p>
<p><span class="Bold"><span class="Emphasis">Adjunctive Treatment in <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac Arrest</span><br></span></span>Infusions of LEVOPHED are usually administered intravenously during cardiac resuscitation to restore and maintain an adequate blood pressure after an effective heartbeat and ventilation have been established by other means. [LEVOPHEDâ€™s powerful beta-adrenergic stimulating action is also thought to increase the strength and effectiveness of systolic contractions once they occur.]</p>
<p><span class="Italics"><span class="Emphasis">Average Dosage:</span></span> To maintain systemic blood pressure during the management of <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, LEVOPHED is used in the same manner as described under Restoration of Blood Pressure in Acute Hypotensive States.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to use, whenever solution and container permit.</p>
<p>Do not use the solution if its color is pinkish or darker than slightly yellow or if it contains a precipitate.</p>
<p>Avoid contact with iron salts, alkalis, or oxidizing agents.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="f4c2e9e0-549a-4fe7-99c8-013b31532489"></a><a name="section-16"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">LEVOPHED (norepinephrine bitartrate) injection, USP, contains the equivalent of 1 mg base of LEVOPHED per 1 mL (4 mg/4 mL).</p>
<p>Supplied as:<br>
    5 mL vials (4 mL fill, 4 mg/4 mL) in boxes of 10 (NDC No. 0409-3375-25)</p>
<p>Store at 20 to 25Â°C (68 to 77Â°F); excursions permitted to 15 to 30Â°C (59 to 86Â°F). <br>
    [See USP Controlled Room Temperature.]</p>
<p>Protect from light.</p>
<p>Regitine, trademark, CIBA Pharmaceuticals Company.</p>
<p>Revised: 01/2013</p>
<p>EN-3061</p>
<p>Mfd. by Hospira, Inc., Lake Forest, IL 60045 USA<br>
    N+ and NOVAPLUS are registered trademarks of Novation, LLC.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="dfa7a712-7203-497f-9ad9-fd9097a149fc"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">CA-3095</span></span></p>
<p><span class="Bold"><span class="Emphasis">Front Panel</span></span></p>
<p><img alt="Carton-NDC 0409-3375-25-Front panel" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2b5320e-e6a6-4a43-8f3c-9c21195ceb4a&amp;name=levophed-injection-usp4-figure-2-ca-3095-frontpanel.jpg"></p>
<p><span class="Bold"><span class="Emphasis">Back Panel</span></span></p>
<p><img alt="Carton-NDC 0409-3375-25-Back panel" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2b5320e-e6a6-4a43-8f3c-9c21195ceb4a&amp;name=levophed-injection-usp4-figure-3-ca-3095-backpanel.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LEVOPHEDÂ 		
					</strong><br><span class="contentTableReg">norepinephrine bitartrate injection, solution, concentrate</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0409-3375</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NOREPINEPHRINE BITARTRATE</strong> (NOREPINEPHRINE) </td>
<td class="formItem">NOREPINEPHRINE</td>
<td class="formItem">1Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM METABISULFITE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0409-3375-25</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">4 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA007513</td>
<td class="formItem">07/13/1950</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Hospira, Inc.
							(141588017)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6de87310-ce59-4c09-8ae9-954f4ac1e9db</div>
<div>Set id: d2b5320e-e6a6-4a43-8f3c-9c21195ceb4a</div>
<div>Version: 1</div>
<div>Effective Time: 20140428</div>
</div>
</div>Â <div class="DistributorName">Hospira, Inc.</div></p>
</body></html>
